Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.37 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.37 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | STS | P08842 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23579323 | 0.86 | NR1H2 (0.53) | NR1H2NAMPTUSP2SMN1; SMN2KAT5 | |
| SCHEMBL23579164 | 0.85 | NR1H2 (0.46) | NR1H2NAMPTKAT5KAT6AKAT8 | |
| SCHEMBL28062963 | 0.81 | NR1H2 (0.54) | NR1H2NAMPTUSP2SMN1; SMN2KAT5 | |
| SCHEMBL21805919 | 0.81 | NR1H2 (0.54) | NR1H2NAMPTUSP2SMN1; SMN2KAT5 | |
| SCHEMBL10293026 | 0.81 | NR1H2 (0.60) | NR1H2NAMPTUSP2SMN1; SMN2MEN1 | |
| SCHEMBL21063626 | 0.79 | NR1H2 (0.58) | NR1H2NAMPTUSP2SMN1; SMN2MEN1 | |
| SCHEMBL24969818 | 0.79 | NR1H2 (0.51) | NR1H2NAMPTUSP2SMN1; SMN2KAT5 | |
| SCHEMBL16415001 | 0.79 | NR1H2 (0.51) | NR1H2NAMPTUSP2SMN1; SMN2GPR119 | |
| SCHEMBL28483368 | 0.79 | NR1H2 (0.51) | NR1H2NAMPTUSP2SMN1; SMN2KAT5 | |
| SCHEMBL31609104 | 0.78 | GPR119 (0.43) | NR1H2KAT5KAT6AKAT8GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289801-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-09-18 | — | — | US | disclosed |
| CN-115135642-B | Inhibitors of EGFR mutant forms | 缆图药品公司 | 2025-03-04 | — | — | CN | disclosed |
| US-12172983-B2 | EGFR inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-12-24 | — | — | US | disclosed |
| US-11718602-B2 | EGFR inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718602-B2 | EGFR inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718602-B2 | EGFR inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230056541-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-02-23 | — | — | US | disclosed |
| US-20230056541-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-02-23 | — | — | US | disclosed |
| US-20230026209-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-01-26 | — | — | US | disclosed |
| US-20230026209-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-01-26 | — | — | US | disclosed |
| EP-4081515-A1 | INHIBITORS OF MUTANT FORMS OF EGFR | Blueprint Medicines Corporation (US) | 2022-11-02 | — | — | EP | disclosed |
| CN-115135642-A | Inhibitors of mutant forms of EGFR | 缆图药品公司 | 2022-09-30 | — | — | CN | disclosed |
| WO-2021133809-A1 | INHIBITORS OF MUTANT FORMS OF EGFR | BLUEPRINT MEDICINES CORPORATION (US) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230056541-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | NR1H2 2807/4885NAMPT 3285/4885USP2 2129/4885 |
| US-20230026209-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | NR1H2 2807/4885NAMPT 3285/4885USP2 2129/4885 |
| US-11718602-B2 | EGFR inhibitors | EGFR, ERBB2, ERBB3 | NR1H2 2807/4885NAMPT 3285/4885USP2 2129/4885 |
| US-12172983-B2 | EGFR inhibitors | EGFR, ERBB2, ERBB3 | NR1H2 2807/4885NAMPT 3285/4885USP2 2129/4885 |
| US-20250289801-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | NR1H2 2807/4885NAMPT 3285/4885USP2 2129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.